| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1.3B | ¥1.2B | +5.8% |
| Operating Income | ¥-2.8B | ¥-2.4B | -20.3% |
| Ordinary Income | ¥-2.7B | ¥-1.8B | -48.3% |
| Net Income | ¥-2.9B | ¥-1.9B | -49.2% |
| ROE | -11.7% | -7.1% | - |
FY2026 Q1 results: Revenue ¥1.3B (YoY +5.8%), Operating Loss ¥-2.8B (YoY -20.3%, loss widened), Ordinary Loss ¥-2.7B (YoY -48.3%, loss widened), Net Loss ¥-2.9B (YoY -49.2%, loss widened). While revenue grew modestly, profitability deteriorated significantly across all levels. Gross profit margin of 31.1% indicates product-level profitability is maintained, but selling, general and administrative expenses of ¥3.3B (246.8% of revenue) drove substantial operating losses. Non-operating income of ¥0.2B, primarily from FX gains of ¥0.1B, partially offset losses. An impairment loss of ¥0.2B was recognized as an extraordinary item. The company maintains strong liquidity with cash and deposits of ¥28.2B representing 94.0% of total assets, though accumulated losses of ¥-26.6B continue to erode equity.
Revenue increased 5.8% YoY to ¥1.3B, driven by modest top-line growth in core operations. Gross profit of ¥0.4B at a 31.1% margin demonstrates that products and services generate positive unit economics. However, cost of sales of ¥0.9B and significantly elevated SG&A expenses of ¥3.3B created severe operating leverage challenges. The SG&A ratio of 246.8% indicates fixed costs far exceed the current revenue base, representing the primary driver of operating losses.
Operating loss expanded 20.3% YoY to ¥-2.8B, with operating margin at -215.2%. This deterioration was driven by SG&A expenses growing faster than revenue, with insufficient scale to absorb fixed cost structures. The year-over-year increase in SG&A outpaced revenue growth, suggesting cost discipline remains a critical challenge.
Non-operating income of ¥0.2B provided partial offset, consisting mainly of FX gains of ¥0.1B and interest income of ¥0.0B. The non-operating net contribution narrowed the gap between operating and ordinary losses by approximately ¥0.1B. Ordinary loss widened 48.3% to ¥-2.7B.
A non-recurring impairment loss of ¥0.2B was recognized in extraordinary losses, indicating asset revaluation or write-downs of underperforming assets. This one-time charge contributed to net loss expansion but signals potential future relief from depreciation or carrying cost burdens.
Net loss deteriorated 49.2% to ¥-2.9B, with loss per share of ¥-7.74 compared to ¥-5.30 in the prior year. The widening gap between ordinary loss and net loss reflects the impact of extraordinary impairment charges. Income tax expense was minimal at ¥0.0B, consistent with the loss-making position.
This represents a revenue up/profit down pattern, where modest revenue growth failed to translate into profitability improvement due to disproportionate cost structure and one-time charges.
[Profitability] ROE of -11.7% reflects significant net losses against equity base, deteriorating from cash-backed earnings generation. Operating margin of -215.2% indicates severe operating leverage challenges with SG&A expenses at 246.8% of revenue. Gross profit margin of 31.1% demonstrates product-level profitability is maintained but insufficient scale prevents fixed cost absorption. [Cash Quality] Cash and deposits of ¥28.2B provide exceptionally strong liquidity, with short-term debt coverage ratio of approximately 5.07x against current liabilities of ¥5.6B. Working capital of ¥23.9B reflects substantial liquidity cushion. [Investment Efficiency] Asset turnover of 0.044x indicates low revenue generation relative to asset base, primarily reflecting cash-heavy balance sheet structure. Financial leverage of 1.23x remains conservative. [Financial Health] Equity ratio of 81.2% represents strong capitalization despite accumulated losses. Current ratio of 530.8% indicates extremely robust short-term liquidity position. Debt-to-equity ratio of 0.23x reflects minimal leverage. Retained earnings of ¥-26.6B, deteriorating from ¥-23.8B in prior year, represents ongoing concern requiring earnings recovery to prevent further equity erosion.
Cash and deposits of ¥28.2B represent 94.0% of total assets, providing substantial liquidity cushion despite operating losses. The cash position serves as critical buffer against ongoing operating losses of ¥-2.8B per quarter. Current assets of ¥29.5B against current liabilities of ¥5.6B yield a current ratio of 530.8%, indicating no immediate liquidity stress. Contract liabilities of ¥4.2B suggest advance customer payments or deferred revenue, potentially providing working capital support. Total assets decreased from ¥30.9B to ¥30.0B, with the decline primarily reflecting equity erosion from net losses rather than asset disposal. The cash-rich balance sheet structure provides runway to fund operations during the monetization phase, though sustained losses of current magnitude would deplete reserves over multiple periods. Working capital remains robust with no evidence of liquidity stress, though the burn rate implied by quarterly losses of ¥-2.9B would require monitoring if profitability inflection is not achieved.
Ordinary loss of ¥-2.7B versus operating loss of ¥-2.8B shows non-operating net contribution of approximately ¥0.1B, consisting primarily of FX gains of ¥0.1B and interest income of ¥0.0B. Non-operating income represents 15.1% of revenue, providing modest offset to operating losses but insufficient to materially improve overall profitability. The extraordinary impairment loss of ¥0.2B represents a non-recurring charge that widened net loss to ¥-2.9B. Excluding this one-time item, recurring losses would approximate ¥-2.7B, still reflecting substantial operating challenges. The quality of earnings is constrained by negative profitability across all levels, with losses driven by structural cost issues rather than revenue deterioration. The absence of operating cash flow data limits assessment of cash conversion, though the cash-backed balance sheet suggests historical cash generation or financing has provided current liquidity reserves. The recurring nature of operating losses and high fixed cost burden indicate earnings quality will remain under pressure until revenue scale improves or cost structure is rationalized.
Annual dividend forecast is ¥0.00 for FY2026, unchanged from prior periods, with no dividend revision this quarter. The company maintains a no-dividend policy consistent with its loss-making position and accumulated deficit of ¥-26.6B. Payout ratio is not applicable given negative earnings. No share buyback activity was disclosed. The absence of shareholder returns reflects management's focus on conserving cash during the monetization phase and prioritizing operational improvement over capital returns. Dividend resumption would require sustained return to profitability and reduction of accumulated losses. The strong cash position of ¥28.2B provides financial capacity for future returns once earnings recovery is achieved, but current financial performance does not support near-term dividend initiation.
Monetization risk: Revenue of ¥1.3B remains insufficient to cover fixed cost base of ¥3.3B in SG&A expenses, with operating margin of -215.2% indicating business model has not achieved commercial viability at current scale. Continued inability to expand revenue or reduce cost structure would extend losses and accelerate equity erosion.
Accumulated deficit risk: Retained earnings of ¥-26.6B deteriorated by ¥2.9B this quarter, with cumulative losses reducing total equity from ¥27.1B to ¥24.4B. Sustained quarterly losses at current magnitude of ¥-2.9B would deplete equity within 8-9 quarters absent revenue growth or cost reduction, potentially necessitating capital raising.
Asset impairment risk: Recognition of ¥0.2B impairment loss this quarter signals asset quality concerns and potential for additional write-downs. Further impairments would increase non-cash charges and reduce book value, though with limited impact on cash-backed operations given strong liquidity position of ¥28.2B.
[Industry Position] (Reference - Proprietary Analysis) Given limited historical trend data for the company and absence of specific industry peer comparisons in available data, industry positioning is assessed based on structural characteristics. The company's operating margin of -215.2% and negative ROE of -11.7% indicate pre-commercialization or early-stage growth phase typical of development-stage enterprises. The equity ratio of 81.2% significantly exceeds typical industry norms for mature operating companies, reflecting capital raised in excess of near-term operating needs. This financial structure is more consistent with venture-backed or pre-revenue companies maintaining cash reserves to fund development and commercialization efforts. The absence of debt leverage and reliance on equity financing suggests limited access to or need for traditional bank financing given the loss-making profile. Contract liabilities of ¥4.2B relative to quarterly revenue of ¥1.3B indicate potential milestone or license-based business model common in technology, pharmaceutical, or intellectual property commercialization sectors. The gross margin of 31.1% falls within acceptable ranges for product businesses but requires substantially higher revenue scale to achieve operating leverage.
Strong liquidity position provides operational runway: Cash and deposits of ¥28.2B representing 94.0% of total assets creates substantial buffer to fund operations during monetization phase, with current quarterly burn rate of approximately ¥-2.9B providing multiple quarters of runway. The current ratio of 530.8% and equity ratio of 81.2% indicate no near-term financial distress despite persistent losses, allowing management time to execute on commercialization strategy without immediate capital constraints.
Cost structure reform is critical priority: SG&A expenses of ¥3.3B representing 246.8% of revenue drive operating losses, with operating margin of -215.2% indicating fundamental misalignment between cost base and revenue scale. The widening of operating losses by 20.3% YoY despite revenue growth of 5.8% demonstrates cost growth is outpacing revenue expansion. Achieving profitability requires either substantial revenue acceleration through successful product commercialization or meaningful fixed cost reduction through operational restructuring. The gross margin of 31.1% confirms product economics are viable, suggesting the path to profitability exists if operating leverage can be achieved.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.